BB Biotech AG Stock
Price
Target price
€57.30
€57.30
1.060%
0.6
1.060%
-
17:08 / Tradegate
WKN: A0NFN3 / Name: BB Biotech / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
BB Biotech AG Stock
There is an upward development for BB Biotech AG compared to yesterday, with an increase of €0.60 (1.060%).
Pros and Cons of BB Biotech AG in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of BB Biotech AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 1.060% | 4.613% | 3.091% | 71.818% | 16.308% | -3.898% | -3.898% |
| Medpace Holdings Inc | -1.030% | 5.109% | 11.286% | 35.311% | 8.703% | 115.000% | 259.315% |
| Galapagos N.V. | -0.560% | 8.377% | -5.980% | -8.542% | -11.412% | -30.885% | -50.567% |
| United Therapeutics | 1.120% | -0.800% | -6.885% | 72.317% | 4.447% | 105.384% | 155.029% |
Comments
News
EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy
EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy
EQS-News: BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning
EQS-News: BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning